Evotec SE reports developments in drug discovery and development services, integrated R&D programs and strategic partnerships with pharmaceutical, biotechnology, academic and health-focused organizations. Its updates commonly cover small-molecule, biologics and cell-therapy work; AI/ML-enabled platforms such as Molecular Patient Databases, PanOmics and iPSC-based disease modeling; and therapeutic programs in oncology, cardiovascular and metabolic disease, neurology, immunology and infectious disease.
Recurring news also includes Just - Evotec Biologics manufacturing and biologics-development activity, grant-funded global-health work, preclinical candidate nominations, financial results and business updates. Governance items include Supervisory Board nominations, management appointments and operating-model changes tied to the company’s global R&D and partnership infrastructure.
Evotec (EVO) appointed Dr. Joanna Holbrook as Chief Scientific Officer and Management Board member, effective November 1, 2026.
She will lead Evotec's global scientific strategy across discovery and development services, technology platforms and proprietary innovation. Holbrook brings more than 25 years of experience in pharmaceuticals, biotechnology and academia. Most recently, she served as Therapy Area Head for Cardiovascular, Renal and Hepatic Disease and Head of in vitro Discovery Platforms at Novo Nordisk. Her previous roles include Chief Scientific Officer at Biomodal and Vice President, Translational Medicine at BenevolentAI.
Evotec (EVO) announced that Chief Scientific Officer Cord Dohrmann will step down on September 30, 2026, by mutual consent.
Dohrmann has served as chief scientific officer and a member of the Management Board since 2010. The search for his successor is ongoing.
Evotec (EVO) has initiated a first-in-human Phase 1 trial of JST-018, a cocktail of investigational monoclonal antibodies targeting orthopoxviruses, developed by its CDMO subsidiary Just – Evotec Biologics under the U.S. Department of War's Accelerated Antibodies Program.
The program advanced from antibody sequence selection through preclinical work, process development, regulatory submission and cGMP manufacturing of clinical material at the J.POD® Redmond, Washington, continuous bioprocessing facility. This milestone fulfills the scope of a 2023 U.S. Department of War contract to progress antibody-based countermeasures against orthopoxviruses into first-in-human evaluation. JST-018 is being developed as a prophylactic therapy for warfighters at elevated risk from biological threats. Together with a prior 2022 plague antibody award, Just – Evotec Biologics’ two contracts under the program have a combined potential value of up to $123.9 million.
Evotec (NASDAQ: EVO) and Plectonic Biotech have entered a research collaboration to evaluate a novel T-cell-engaging immunotherapy concept for solid tumors. The partners will combine Plectonic's programmable, logic-gated LOGIBODY® DNA-protein therapeutics with Evotec's proprietary BiTco platform, which uses a non-blocking CD2 antibody to provide additional costimulatory signals to T cells.
The collaboration aims to generate preclinical proof-of-concept data on whether highly selective multi-antigen tumor recognition, paired with CD2-mediated T cell co-stimulation, can improve the precision, potency and safety window of T-cell-engager approaches in solid tumors. Both companies have previously reported preclinical data supporting their respective platforms.
Evotec (NASDAQ: EVO) announced a strategic R&D collaboration with Odyssey Therapeutics (NASDAQ: ODTX) to discover potential new small molecule treatments for autoimmune and inflammatory diseases. Odyssey will use Evotec's integrated, AI-enabled discovery platform, advanced screening capabilities and proprietary compound libraries across multiple high-value disease targets.
The collaboration combines Odyssey's expertise in autoimmune and inflammatory disease biology with Evotec's data-driven discovery infrastructure, aiming to accelerate identification of validated hit series and early-stage programs. According to Evotec, it is eligible to receive milestone payments tied to successful delivery of validated hit series for each target; detailed financial terms were not disclosed.
Niagen Bioscience (NASDAQ: NAGE) has selected Evotec (NASDAQ: EVO; FSE: EVT) as contract research organization to advance preclinical development of NB4168, an oral small-molecule candidate for Ataxia Telangiectasia (A-T). Evotec will run pharmacokinetic, pharmacodynamic and bioanalytical studies at its Verona, Italy campus using its INDiGO platform.
According to Niagen Bioscience, nonclinical data show substantially higher blood exposure for NB4168 versus NR chloride. NB4168 has received U.S. FDA Rare Pediatric Disease Designation and EMA Orphan Medicinal Product Designation for A-T. The company is progressing IND-enabling work and plans to submit an IND to begin human clinical studies.
Evotec (NASDAQ: EVO; Frankfurt: EVT) has selected Navan (NASDAQ: NAVN), an AI-powered business travel and expense platform, to manage Evotec’s corporate travel and expense program in key global markets. Evotec will roll out Navan in Germany, the UK, U.S., Italy, and France to replace fragmented country-level tools and manual offline processes.
According to both companies, the unified platform is intended to simplify employee user experience, automate reconciliation from the point of swipe, and support greater consistency, transparency, and efficiency in Evotec’s travel and expense management.
Evotec (NASDAQ: EVO; Frankfurt: EVT) released preliminary, unaudited figures for Q2 and the first half of 2026 and revised its full-year 2026 outlook. For H1 2026, Evotec expects Group revenues of about €300.1 million and adjusted Group EBITDA of about -€42.7 million, with liquidity around €465.6 million as of 30 June 2026.
For full-year 2026, Evotec now forecasts Group revenues of approximately €570–610 million (€595–635 million CER) and adjusted Group EBITDA of approximately -€70 to -105 million (-€60 to -90 million CER. Previous guidance was €700–780 million (€730–810 million CER) for revenues and €0–40 million (€10–50 million CER) for adjusted EBITDA.
Evotec (NASDAQ: EVO) launched J.TRAIN, a turnkey model that lets biopharma partners deploy Just – Evotec Biologics’ proprietary continuous manufacturing platform inside their own facilities. The solution combines modular cleanrooms, standard equipment and cGMP-compliant automation to support faster, lower-cost capacity expansion versus traditional fed-batch plants.
J.TRAIN targets deployment in about 18 months and can produce over 500 kg of biologic drug substance from under 10,000 sq ft, which Evotec says exceeds ten times the productivity of conventional methods while enabling flexible, multi-product manufacturing.
Evotec (NASDAQ:EVO) reported results of its Annual General Meeting 2026 held in Hamburg, Germany.
All agenda items were adopted with the required majority. Shareholders elected Dieter Weinand and Dr. Wolfgang Hofmann to the Supervisory Board, and re-elected Dr. Duncan McHale and Wesley Wheeler. Weinand was appointed Chairman. 43.10% of registered share capital was represented.